128 related articles for article (PubMed ID: 28588683)
21. Humoral immune responses of cancer patients against "Cancer-Testis" antigen NY-ESO-1: correlation with clinical events.
Jäger E; Stockert E; Zidianakis Z; Chen YT; Karbach J; Jäger D; Arand M; Ritter G; Old LJ; Knuth A
Int J Cancer; 1999 Oct; 84(5):506-10. PubMed ID: 10502728
[TBL] [Abstract][Full Text] [Related]
22. NY-ESO-1 protein formulated in ISCOMATRIX adjuvant is a potent anticancer vaccine inducing both humoral and CD8+ t-cell-mediated immunity and protection against NY-ESO-1+ tumors.
Maraskovsky E; Sjölander S; Drane DP; Schnurr M; Le TT; Mateo L; Luft T; Masterman KA; Tai TY; Chen Q; Green S; Sjölander A; Pearse MJ; Lemonnier FA; Chen W; Cebon J; Suhrbier A
Clin Cancer Res; 2004 Apr; 10(8):2879-90. PubMed ID: 15102697
[TBL] [Abstract][Full Text] [Related]
23. Comparisons for detecting NY-ESO-1 mRNA expression levels in hepatocellular carcinoma tissues.
Wang XY; Chen HS; Luo S; Zhang HH; Fei R; Cai J
Oncol Rep; 2009 Mar; 21(3):713-9. PubMed ID: 19212631
[TBL] [Abstract][Full Text] [Related]
24. NY-ESO-1 expression and its serum immunoreactivity in esophageal cancer.
Akcakanat A; Kanda T; Koyama Y; Watanabe M; Kimura E; Yoshida Y; Komukai S; Nakagawa S; Odani S; Fujii H; Hatakeyama K
Cancer Chemother Pharmacol; 2004 Jul; 54(1):95-100. PubMed ID: 15118836
[TBL] [Abstract][Full Text] [Related]
25. Ny-ESO-1 expression and immunogenicity associated with transitional cell carcinoma: correlation with tumor grade.
Kurashige T; Noguchi Y; Saika T; Ono T; Nagata Y; Jungbluth A; Ritter G; Chen YT; Stockert E; Tsushima T; Kumon H; Old LJ; Nakayama E
Cancer Res; 2001 Jun; 61(12):4671-4. PubMed ID: 11406534
[TBL] [Abstract][Full Text] [Related]
26. Heteroclitic serological response in esophageal and prostate cancer patients after NY-ESO-1 protein vaccination.
Kawada J; Wada H; Isobe M; Gnjatic S; Nishikawa H; Jungbluth AA; Okazaki N; Uenaka A; Nakamura Y; Fujiwara S; Mizuno N; Saika T; Ritter E; Yamasaki M; Miyata H; Ritter G; Murphy R; Venhaus R; Pan L; Old LJ; Doki Y; Nakayama E
Int J Cancer; 2012 Feb; 130(3):584-92. PubMed ID: 21413013
[TBL] [Abstract][Full Text] [Related]
27. NY-ESO-1 and LAGE-1 cancer-testis antigens are potential targets for immunotherapy in epithelial ovarian cancer.
Odunsi K; Jungbluth AA; Stockert E; Qian F; Gnjatic S; Tammela J; Intengan M; Beck A; Keitz B; Santiago D; Williamson B; Scanlan MJ; Ritter G; Chen YT; Driscoll D; Sood A; Lele S; Old LJ
Cancer Res; 2003 Sep; 63(18):6076-83. PubMed ID: 14522938
[TBL] [Abstract][Full Text] [Related]
28. Expression of SSX-1 and NY-ESO-1 mRNA in tumor tissues and its corresponding peripheral blood expression in patients with hepatocellular carcinoma.
Lu Y; Wu LQ; Lü ZH; Wang XJ; Yang JY
Chin Med J (Engl); 2007 Jun; 120(12):1042-6. PubMed ID: 17637219
[TBL] [Abstract][Full Text] [Related]
29. [Correlation of NY-ESO-1 gene and protein expression to metastasis and clinicopathologic features of hepatocellular carcinoma].
Zhang WM; Xiao G; Xie D; Zhang M; Guo AL; Wen JM
Ai Zheng; 2005 May; 24(5):622-6. PubMed ID: 15890110
[TBL] [Abstract][Full Text] [Related]
30. Application of serum NY-ESO-1 antibody assay for early SCLC diagnosis.
Yang J; Jiao S; Kang J; Li R; Zhang G
Int J Clin Exp Pathol; 2015; 8(11):14959-64. PubMed ID: 26823828
[TBL] [Abstract][Full Text] [Related]
31. Serum NY-ESO-1 and p53 antibodies as useful tumor markers in gastric cancer.
Kawada J; Saito T; Kurokawa Y; Kawabata R; Takeno A; Takeoka T; Nose Y; Wada H; Eguchi H; Doki Y;
Ann Gastroenterol Surg; 2024 Mar; 8(2):243-250. PubMed ID: 38455491
[TBL] [Abstract][Full Text] [Related]
32. Predictive and prognostic effect of CD133 and cancer-testis antigens in stage Ib-IIIA non-small cell lung cancer.
Su C; Xu Y; Li X; Ren S; Zhao C; Hou L; Ye Z; Zhou C
Int J Clin Exp Pathol; 2015; 8(5):5509-18. PubMed ID: 26191258
[TBL] [Abstract][Full Text] [Related]
33. Immunohistochemical analysis of NY-ESO-1 antigen expression in normal and malignant human tissues.
Jungbluth AA; Chen YT; Stockert E; Busam KJ; Kolb D; Iversen K; Coplan K; Williamson B; Altorki N; Old LJ
Int J Cancer; 2001 Jun; 92(6):856-60. PubMed ID: 11351307
[TBL] [Abstract][Full Text] [Related]
34. Antibody response against NY-ESO-1 in CHP-NY-ESO-1 vaccinated patients.
Kawabata R; Wada H; Isobe M; Saika T; Sato S; Uenaka A; Miyata H; Yasuda T; Doki Y; Noguchi Y; Kumon H; Tsuji K; Iwatsuki K; Shiku H; Ritter G; Murphy R; Hoffman E; Old LJ; Monden M; Nakayama E
Int J Cancer; 2007 May; 120(10):2178-84. PubMed ID: 17278093
[TBL] [Abstract][Full Text] [Related]
35. The spontaneous CD8+ T-cell response to HLA-A2-restricted NY-ESO-1b peptide in hepatocellular carcinoma patients.
Shang XY; Chen HS; Zhang HG; Pang XW; Qiao H; Peng JR; Qin LL; Fei R; Mei MH; Leng XS; Gnjatic S; Ritter G; Simpson AJ; Old LJ; Chen WF
Clin Cancer Res; 2004 Oct; 10(20):6946-55. PubMed ID: 15501973
[TBL] [Abstract][Full Text] [Related]
36. Frequency of NY-ESO-1 and LAGE-1 expression in bladder cancer and evidence of a new NY-ESO-1 T-cell epitope in a patient with bladder cancer.
Sharma P; Gnjatic S; Jungbluth AA; Williamson B; Herr H; Stockert E; Dalbagni G; Donat SM; Reuter VE; Santiago D; Chen YT; Bajorin DF; Old LJ
Cancer Immun; 2003 Dec; 3():19. PubMed ID: 14680360
[TBL] [Abstract][Full Text] [Related]
37. Urine antibody against human cancer antigen NY-ESO-1.
Jäger D; Stockert E; Karbach J; Herrlinger K; Atmaca A; Arand M; Chen YT; Gnjatic S; Old LJ; Knuth A; Jäger E
Cancer Immun; 2002 Aug; 2():10. PubMed ID: 12747755
[TBL] [Abstract][Full Text] [Related]
38. Diagnostic and therapeutic relevance of NY-ESO-1 expression in oral squamous cell carcinoma.
Ries J; Mollaoglu N; Vairaktaris E; Neukam FW; Nkenke E
Anticancer Res; 2009 Dec; 29(12):5125-30. PubMed ID: 20044626
[TBL] [Abstract][Full Text] [Related]
39. Cancer-testis antigen expression in synovial sarcoma: NY-ESO-1, PRAME, MAGEA4, and MAGEA1.
Iura K; Maekawa A; Kohashi K; Ishii T; Bekki H; Otsuka H; Yamada Y; Yamamoto H; Harimaya K; Iwamoto Y; Oda Y
Hum Pathol; 2017 Mar; 61():130-139. PubMed ID: 27993576
[TBL] [Abstract][Full Text] [Related]
40. Treatment with decitabine induces the expression of stemness markers, PD-L1 and NY-ESO-1 in colorectal cancer: potential for combined chemoimmunotherapy.
Taib N; Merhi M; Inchakalody V; Mestiri S; Hydrose S; Makni-Maalej K; Raza A; Sahir F; Azizi F; Nizamuddin PB; Fernandes Q; Yoosuf ZSKM; Almoghrabi S; Al-Zaidan L; Shablak A; Uddin S; Maccalli C; Al Homsi MU; Dermime S
J Transl Med; 2023 Mar; 21(1):235. PubMed ID: 37004094
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]